anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine composition for treating pig gastric ulcer. The traditional Chinese medicine composition is prepared from pinellia tubers, radix scutellariae, dried ginger, ginseng, licorice, rhizoma coptidis, Chinese dates, ginger, monkshood, medicinal evodia fruits and golden buckwheat rhizomes. The traditional Chinese medicine composition can be powder. The traditional Chinese medicine composition is prepared through the following steps: (1) weighing traditional Chinese medicines namely 10-16 parts of pinellia tubers, 8-15 parts of radix scutellariae, 6-13 parts of dried ginger, 8-12 parts of ginseng, 5-7 parts of licorice, 5-8 parts of rhizoma coptidis, 10-15 parts of Chinese dates, 7-10 parts of ginger, 5-10 parts of monkshood, 7-12 parts of medicinal evodia fruits, and 5-9 parts of golden buckwheat rhizomes according to a formula; (2) crushing the traditional Chinese medicines and screening the crushed traditional Chinese medicines with a 40-80-mesh sieve; (3) mixing the screened traditional Chinese medicines for 10-20 minutes to obtain traditional Chinese medicine powder; (4) subpackaging the traditional Chinese medicine powder according to the fact that each bag is filled with 100-200 g of the traditional Chinese medicine powder to obtain finished products. The traditional Chinese medicine composition provided by the invention can effectively treat the pig gastric ulcer, and the cure rate is more than 95%. The formula has the efficacies of warming the stomach, preventing or arresting vomiting, eliminating cold to stop pain, supplementing qi and nourishing blood.
PURPOSE:To obtain a remedy for oral administration, having low toxicity and effective in remedying acute and chronic human or mammal hepatic diseases caused by various causes, e.g. alcoholic hepatitis and cirrhosis, by using an alicyclic dicarboxylic acid imide as an active component. CONSTITUTION:An alicyclic dicarboxylic acid imide compound of formula I (X is halogen; n is 1-5) is used as an active component. The compound of formula I is dispersed in conventional carrier or diluent and used in the form of peroral drug such as tablet, granule and liquid. The compound of formula I is known compound effective as an agricultural disinfectant and can be synthe sized by the dehydrative condensation of a compound of formula III in a solvent such as acetic acid at 20-250 deg.C. A concrete example of the compound of formu la I is N-(2-fluorophenyl)-7-oxabicyclo[2,2,1]hept-5-ene-2,3-dicarboxyimide.
BACKGROUND: Liver transplantation (LT) is the treatment of choice for end-stage liver disease and certain malignancies such as hepatocellular carcinoma (HCC). Data on the surgical management of de novo or recurrent tumors that develop in the transplanted allograft are limited. This study aimed to investigate the perioperative and long-term outcomes for patients undergoing hepatic resection for de novo or recurrent tumors after liver transplantation.
METHODS: The study enrolled adult and pediatric patients from 12 centers across North America who underwent hepatic resection for the treatment of a solid tumor after LT. Perioperative outcomes were assessed as well as recurrence free survival (RFS) and overall survival (OS) for those undergoing resection for HCC.
RESULTS: Between 2003 and 2023, 54 patients underwent hepatic resection of solid tumors after LT. For 50 patients (92.6 %), resection of malignant lesions was performed. The most common lesion was HCC (n = 35, 64.8 %), followed by cholangiocarcinoma (n = 6, 11.1 %) and colorectal liver metastases (n = 6, 11.1 %). The majority of the 35 patients underwent resection of HCC did not receive any preoperative therapy (82.9 %) or adjuvant therapy (71.4 %), with resection their only treatment method for HCC. During a median follow-up period of 50.7 months, the median RFS was 21.5 months, and the median OS was 49.6 months.
CONCLUSION: Hepatic resection following OLT is safe and associated with morbidity and mortality rates that are comparable to those reported for patients undergoing resection in native livers. Hepatic resection as the primary and often only treatment modality for HCC following LT is associated with acceptable RFS and OS and should be considered in well selected patients.
BACKGROUND: A national point prevalence survey (PPS) of healthcare-associated infections (HAI) and antibiotic use (AU) was carried out in Germany in 2022 in the framework of the European PPS conducted by the European Centre for Disease Prevention and Control (ECDC). The objective was to determine the prevalence of HAI and AU in German hospitals and to compare the obtained values with those of the most recent previous PPS, which was carried out in 2016.
METHODS: The German National Reference Center for the Surveillance of Nosocomial Infections was entrusted with the organization of the PPS of 2022. As recommended by the ECDC, each hospital in a representative sample of 50 hospitals was invited to participate, and all other interested hospitals in Germany were also able to participate if desired. The data were collected by specially trained hospital staff in May, June, and July 2022. The definitions and methods put forth by the ECDC were used.
RESULTS: Data from 66 586 patients in 252 hospitals were included. The prevalence of HAI in all participating hospitals was 4.9%, and that of AU was 26.9%. The HAI and AU prevalences were essentially unchanged in comparison to 2016. The most common types of HAI were surgical site infection (23.5%), lower respiratory tract infection (21.6%), and urinary tract infection (19.0%).
CONCLUSION: HAI were just as frequent in 2022 as in 2016, affecting approximately one in twenty hospitalized patients on any given day.
1,261,777. Bacterial endotoxins. ABBOTT LABORATORIES. 1 Dec., 1969 [16 Dec., 1968], No. 58656/69. Heading A5B. Bacterial endotoxins of reduced toxicity are prepared by dissolving a bacterial lipopolysaccharide in a non-aqueous solvent, adding a dibasic acid anhydride to the lipopolysaccharide solution, agitating for a time sufficient to acylate the lipopolysaccharide and removing the solvent by dialysis. An alkaline reagent which forms a salt with the acid groups derived from the anhydride may also be present. The product may be admixed with an immunogenic adjuvant obtained by (a) reacting a bacterial endotoxin lipopolysaccharide with a haloacyl halide and (b) reacting the haloacylated product with a protein antigen.
BACKGROUND: MAPT is a causative gene in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), a hereditary degenerative disease with various clinical manifestations, including progressive supranuclear palsy, corticobasal syndrome, Parkinson's disease, and frontotemporal dementia.
OBJECTIVES: To analyze genetically, biochemically, and pathologically multiple members of two families who exhibited various phenotypes of the disease.
METHODS: Genetic analysis included linkage analysis, homozygosity haplotyping, and exome sequencing. We conducted tau protein microtubule polymerization assay, heparin-induced tau aggregation, and western blotting with brain lysate from an autopsy case. We also evaluated abnormal tau aggregation by using anti-tau antibody and PM-PBB3.
RESULTS: We identified a variant, c.896_897insACA, p.K298_H299insQ, in the MAPT gene of affected patients. Similar to previous reports, most patients presented with atypical parkinsonism. Biochemical analysis revealed that the mutant tau protein had a reduced ability to polymerize microtubules and formed abnormal fibrous aggregates. Pathological study revealed frontotemporal lobe atrophy, midbrain atrophy, depigmentation of the substantia nigra, and four-repeat tau-positive inclusions in the hippocampus, brainstem, and spinal cord neurons. The inclusion bodies also stained positively with PM-PBB3.
CONCLUSIONS: This study confirmed that the insACA mutation caused FTDP-17. The affected patients showed symptoms resembling Parkinson's disease initially and symptoms of progressive supranuclear palsy later. Despite the initial clinical diagnosis of frontotemporal dementia in the autopsy case, the spread of lesions could explain the process of progressive supranuclear palsy. The study of more cases in the future will help clarify the common pathogenesis of MAPT mutations or specific pathogeneses of each mutation.
The invention concerns a human cytochrome comprising protein 10 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammations etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human cytochrome comprising protein 10.
This clinical study involves two groups of patients with advanced breast cancer. One group (2/3rds of all the patients) will be taking tipifarnib in combination with another anticancer drug called letrozole, and the other group (1/3rd of all the patients) will be taking letrozole plus a placebo (an inactive substance given in the same form as a real drug). The assignment to one of these two groups will be by chance (like flipping a coin). Unless the need arises, neither the patient nor the study staff will know whether the patient is receiving tipifarnib with the letrozole. Comparisons between the two groups will be made for patients who have achieve a confirmed Complete Response (CR) or Partial Response (PR). The interval between the date of randomization and the earliest date of disease progression will also be assessed. The study will include evaluations of safety and tolerability. Patients should expect their participation in this trial to last a minimum of 4 to 8 weeks. Their participation could continue for several months or beyond a year, depending on how their disease responds to the treatment. After completing study treatment, patients will be asked to attend for an End of Treatment visit and then a posttreatment Follow-up visit 4 to 6 weeks after stopping the medication. Patients will be randomly assigned to treatment with either 2.5 mg letrozole once daily plus placebo to match tipifarnib twice daily, or 2.5 mg letrozole once daily plus 300 mg tipifarnib twice daily. Both tipifranib and matching placebo will be given in 28-day cycles of 21 days of treatment followed by 7 days rest. All patients will receive continuous treatment with letrozole.
PROBLEM TO BE SOLVED: To access medical information on a health care apparatus via a communication network. SOLUTION: This health care device 10 includes a web server 14 for transferring a message with a web client by using HTTP(hyper text transfer protocol) and HTML(hyper text mark-up language) open protocol. The server 14 processes an HTTP command designating a prescribed URL of the device 10. The HTTP command is used by a client to read measured data and optional medical information, including optional related information from the device 10. The server 14 constitutes the medical information to an HTML format and transfers this information to the web client which requests an HTTP protocol through its use. A health care person at an arbitrary place accessable to internet can make access to measured data and related information of the device 10 by using a web browser 40.
NEW MATERIAL:3-Hydroxy-4-(hydroxymethyl)benzoic acid expressed by formula I and a salt thereof. USE:A medicine, which is a substance, having immunological activating action without cytotoxicity, and useful for immunological deficiency disease of an organisms with cancer, immunization and chemotherapy of cancer and prevention of metastasis. PREPARATION:An ester expressed by formula II (R<1> is alkyl; R<2> is H or lower alkyl) is reduced in the presence of a reducing agent, e.g. NaBH4, in a solvent, e.g. absolute methanol, at room temperature- while heating, etc. and the residual ester groups are hydrolyzed in the presence of an alkali (earth) metal hydroxide, e.g. NaOH, in an organic solvent, e.g. methanol, at room temperature- while heating to afford the aimed compound expressed by formula I.
INTRODUCTION: Deep learning models for detecting episodes of atrial fibrillation (AF) using rhythm information in long-term ambulatory ECG recordings have shown high performance. However, the rhythm-based approach does not take advantage of the morphological information conveyed by the different ECG waveforms, particularly the f-waves. As a result, the performance of such models may be inherently limited.
METHODS: To address this limitation, we have developed a deep learning model, named RawECGNet, to detect episodes of AF and atrial flutter (AFl) using the raw, single-lead ECG. We compare the generalization performance of RawECGNet on two external data sets that account for distribution shifts in geography, ethnicity, and lead position. RawECGNet is further benchmarked against a state-of-the-art deep learning model, named ArNet2, which utilizes rhythm information as input.
RESULTS: Using RawECGNet, the results for the different leads in the external test sets in terms of the F1 score were 0.91-0.94 in RBDB and 0.93 in SHDB, compared to 0.89-0.91 in RBDB and 0.91 in SHDB for ArNet2. The results highlight RawECGNet as a high-performance, generalizable algorithm for detection of AF and AFl episodes, exploiting information on both rhythm and morphology.
This study is an open, prospective, single-center observational clinical study to evaluate the efficacy and safety of immediate adjuvant ADT with darotarolimide in the treatment of patients with positive lymph nodes after radical prostatectomy for prostate cancer. The study evaluates the efficacy of immediate adjuvant ADT with darotarolimide in patients with positive lymph nodes after radical prostatectomy for prostate cancer, using time to achieve CRPC as the primary study endpoint. OS will be examined in all patients after the primary study endpoint is achieved and will serve as the key secondary study endpoint. It is planned to enroll 108 patients with positive lymph nodes after radical prostatectomy for prostate cancer. It is divided into a screening period, a treatment period and a follow-up period. Patients will enter the screening period from the time they sign the informed consent form, and those who have been evaluated and qualified in the screening period will be entered into the study. Patients eligible for enrollment will receive 2 years of ADT treatment or ADT treatment + darotarotide adjuvant therapy with or without combination radiotherapy at the investigator's discretion.
Infants born to African-American and/or low SES women appear to be at increased risk of adverse effects due to prenatal exposure to alcohol. Computer-delivered SBIRT approaches may provide consistent screening and evidence-based brief interventions, at low cost, without requiring substantial investments of time or energy from medical staff. However, several Stage I steps are necessary before moving to a Stage II clinical trial. This R34 application will therefore lay the groundwork for a fully powered clinical trial of a computer-delivered SBIRT for alcohol use during pregnancy. It will do so through the conduct of five key preliminary studies, including: (1) evaluation of the utility of handheld mobile devices and an anonymous self-interview format in screening for at-risk drinking among patients attending a prenatal clinic; (2) modification of an existing computer-delivered motivational intervention for alcohol use during pregnancy, to previously set standards of acceptability (to experts as well as representative pregnant women); (3) development of an evidence-based tailored messaging supplement to the single-session brief intervention; (4) examining the validity of, and cut scores for, the biomarker Ethyl Glucoronide (EtG) in pregnant women; and (5) collecting data on the acceptability, feasibility, and estimated effect size of the modified computer-delivered intervention through an N = 50 Phase I randomized clinical trial. Participants in this trial will be a diverse sample of women at-risk for alcohol use during pregnancy, the majority of whom will be African-American and/or low SES. These key preparatory steps will greatly facilitate the subsequent development of an R01 application to conduct a Stage II clinical trial for alcohol use during pregnancy. These steps will also provide important preliminary data on (a) a novel method for risk factor screening in primary care; (b) the potential utility of EtG as a biomarker for alcohol use during pregnancy and in the perinatal period; and (c) the effect size estimate for a fully computer-delivered, combined brief interactive/tailored messaging intervention requiring only a single contact. If successful, this line of research could lead to a highly cost-effective, high-reach intervention for alcohol use during pregnancy; these reductions in alcohol use could in turn have a meaningful population impact on Fetal Alcohol Spectrum Disorders.
BACKGROUND: Data on the incidence and clinical relevance of gallstones in patients with suspected acute alcoholic pancreatitis are lacking and are essential to minimize the risk of recurrent acute pancreatitis. The aim of this study was to assess the incidence of gallstones and the associated rate of recurrent acute pancreatitis in patients with presumed acute alcoholic pancreatitis.
METHODS: Between 2008 and 2019, 23 hospitals prospectively enrolled patients with acute pancreatitis. Those diagnosed with their first episode of presumed acute alcoholic pancreatitis were included in this study. The term gallstones was used to describe the presence of cholelithiasis or biliary sludge found during imaging. The primary outcome was pancreatitis recurrence during 3 years of follow-up.
RESULTS: A total of 334 patients were eligible for inclusion, of whom 316 were included in the follow-up analysis. Gallstone evaluation, either during the index admission or during follow-up, was performed for 306 of 334 patients (91.6%). Gallstones were detected in 54 patients (17.6%), with a median time to detection of 6 (interquartile range 0-42) weeks. During follow-up, recurrent acute pancreatitis occurred in 121 of 316 patients (38.3%), with a significantly higher incidence rate for patients with gallstones compared with patients without gallstones (59% versus 34.2% respectively; P < 0.001), while more patients with gallstones had stopped drinking alcohol at the time of their first recurrence (41% versus 24% respectively; P = 0.020). Cholecystectomy was performed for 19 patients with gallstones (36%). The recurrence rate was lower for patients in the cholecystectomy group compared with patients who did receive inadequate treatment or no treatment (5/19 versus 19/34 respectively; P = 0.038).
CONCLUSION: Gallstones were found in almost one in every five patients diagnosed with acute alcoholic pancreatitis. Gallstones were associated with a higher rate of recurrent pancreatitis, while undergoing cholecystectomy was associated with a reduction in this rate.
Valvular heart disease is common in China, either rheumatic or degenerative, and valvular repair or replacement surgery is the important therapeutic method. In all forms of heart valvular disease, combined coronary artery disease worsens perioperative prognosis. Preoperative detection of combined coronary artery disease with invasive coronary angiography is recommended in most patients scheduled for valve surgery, while incidence rate of coronary artery disease in patients with valvular disease showed that only 3%-19% patients were diagnosed with significant stenosis. Although invasive coronary angiography is considered a safe procedure, it still carries a small risk of major (death, stroke, or vascular dissection) and minor (inguinal hematoma) complications. Furthermore, the catheterization procedure is rather expensive, as its invasive nature involves admission to a hospital and requires surveillance by an experienced team. As a non-invasive alternative diagnosis procedure, coronary computed tomographic angiography has showed promising performance with high negative predictive value (95%-100%). Furthermore, computed tomography is a noninvasive procedure with low risk and cost, and it can be easily performed at the clinic. Except for evaluation of coronary artery, computed tomography can also provide information of lung, mediastinum and cardiac structure, which may help physicians make early diagnosis and treatment. Computed tomography is not routinely utilized in clinical practice.

Our study is a prospective multicenter study to assess the feasibility and safety of adding computed tomography as a gatekeeper and perform invasive coronary angiography selectively prior to valvular surgeries.
PROBLEM TO BE SOLVED: To provide a cosmetic patch which can effectively allow a physiologically active component to permeate the skin, has reduced skin irritation, can apply for a long time, and excels in a moist effect.SOLUTION: The patch rejects the use of a support sheet to remove skin irritation which is a common defect of the conventional patches, and the base material is composed of a styrenic thermoplastic elastomer and an oil ingredient, and the main component of the oil ingredient is a liquid hydrocarbon, and the patch is a beauty sheet prepared by dipping this base material in an oily cosmetic liquid. As the composition of the base material, the oil ingredient is set at 100-800 pts.wt. based on 100 pts.wt. styrenic thermoplastic elastomer. When this beauty sheet is applied to the face, the base material is not directly attached to the skin and a thin film (a moist layer) of the oily cosmetic liquid is present between the base material and the skin. Accordingly, the adhesion of the base material to the skin is improved even if it is weak, and moreover, the moist effect on the skin is high and the touch becomes good.
PURPOSE:The titled pharmaceutical containing a formulation of microbial cells of Streptococcus lactis as an active constituent. CONSTITUTION:A radition injury protector containing a formulation of microbial cells of Streptococcus lactis (S.lactis) having superoxide dismutase activity as an active constituent. The radiation injury seem likely to be caused by action of free radicals produced by indirect action of radiation, i.e. ioinizing action thereof and the oxygen effect has the maximum influence. This means that superoxide radicals formed in a xanthine oxidase systems give disorder to cell membranes to induce inactivity of tissues. The above-mentioned protector is, as necessary, incorporated with an adjuvant component and orally or parenterally administered in the form of powder, granule, tablet, capsule, injection, etc., according to the kind of the above-mentioned adjuvant component. The dose thereof is preferably 3-60g/human/day expressed in terms of the formulation of microbial cells.